Skip to content

Breakthrough Therapies for Skin Diseases™

Alphyn Doses First Patient in Phase 2b Clinical Trial of Zabalafin Hydrogel for Atopic Dermatitis

Alphyn
Breakthrough Therapies for Skin Diseases
Alphyn
  • About
    • What We Do
    • Leadership & Board
    • Science Advisory
  • Platform
    • Zabalafin Platform
  • Pipeline
    • Atopic Dermatitis
    • Epidermolysis Bullosa
  • News
    • Press Releases
    • In the News
    • Clinical Presentations
    • Events
  • Contact Us
  • About
    • What We Do
    • Leadership & Board
    • Science Advisory
  • Platform
    • Zabalafin Platform
  • Pipeline
    • Atopic Dermatitis
    • Epidermolysis Bullosa
  • News
    • Press Releases
    • In the News
    • Clinical Presentations
    • Events
  • Contact Us

Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis

by Urtė Fultinavičiūtė

Alphyn Logo 1

NEWS PROVIDED BY
Alphyn Biologics
July 26, 2023

Alphyn is planning to open sites in the US, Canada, Europe and Australia.

Read the Clinical Trials Arena article here.

CONTACTS

 

Corporate:
Neal Koller
[email protected]
(410) 690-8687

 

Media:
Susan Thomas
[email protected]
(619) 540-9195

BREAKTHROUGH THERAPIES FOR SKIN DISEASESTM

Alphyn Biologics is a life science company creating a new class of drugs, Multi-Target Therapeutics® (MTT™), for more powerful and effective therapies.

Our Mission is to create breakthrough therapies for skin diseases – the most difficult, severe and prevalent.

Navigation
  • Home
  • About
    • About Alphyn
    • What We Do
    • Leadership & Board
    • Science Advisory
  • Platform
    • Platform
    • AB-101 Multi-Target Therapeutics
  • Pipeline
    • Pipeline
    • Atopic Dermatitis
    • Epidermolysis Bullosa
  • News
    • News
    • Press Releases
    • In the News
    • Clinical Presentations
    • Events
  • Contact Us

Copyright 2025, Alphyn Biologics, Inc. All rights reserved. | Website Design by ABWeb Beacon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to Top